The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients

Tohoku Journal of Experimental Medicine

Volumn 204, Issue 4, 2004, Pages 249-256

  Cakmak, Gulfidan ^a,b   Demir, Tuncalp ^a   Gemicioglu, Bilun ^a   Aydemir, Akin ^a   Serdaroglu, Emel ^a   Donma, Orkide ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Asthma; Eosinophilic cationic protein; Inhaled steroid; Total antioxidant capacity; Zafirlukast

Indexed keywords

ANTIOXIDANT; BUDESONIDE; EOSINOPHIL CATIONIC PROTEIN; METHACHOLINE; PLACEBO; ZAFIRLUKAST;

ADD ON THERAPY; ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIOXIDANTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PLACEBOS; RESPIRATORY FUNCTION TESTS; TOSYL COMPOUNDS;

EID: 10244257730     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.204.249     Document Type: Article

References (37)

1. Abraham, W.M. (1997) Reactive oxygen species. In: Asthma edited by P.J. Barnes, M.M. Grunstein, A.R. Leff & A.J. Woolcock, Philadelphia, Asthma, 627-638.
2. American Thoracic Society (2000) Guidelines for methacholine and exercise challenge testing-1999. Am. J. Respir. Crit. Care Med. 161, 309-329.
3. Barnes, N.C., Black, B., Syrett, N. & Cojn, J. (1996) Reduction of exacerbation of asthma in multinational clinical trials with zafirlukast. Allergy, 51, Suppl. 30, 84s.
4. Barnes, P.J. (1996) Mechanisms of action of glucocorticoids in asthma. Am. J. Respir. Crit. Care Med., 154, 521-527.
5. Barnes, P.J., Pederson, S. & Busse, W.W. (1998) Inhaled corticosteroids in COPD. Am. J. Respir. Crit. Care Med., 157, 3-11.
6. Calhoun, W.J., Williams, K.L., Simonson, S.G. & Lavins, B.J. (1997) Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am. J. Respir. Crit. Care Med., 155, A662.
7. Calhoun, W.J. (1998) The impact of antileukotriene therapy on markers of airway inflammation. Eur. Respir. Rev., 8, 374-377.
8. Calhaun, W.J., Lavins, B.J., Minkwitz, M.C., Evans, R., Gleich, G.J. & Cohn, J. (1998) Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care Med., 157, 1381-1389.
9. Dahlen, S.E. (1998) Leukotrienes as common mediators of airway obstruction evoked by many trigger factors in asthma. Eur. Respir. Rev., 8, 369-373.
10. Demir, T., Talasli, I., Yaman, M. & Gemicioglu, B. (1999) Serum ECP levels of mild, moderate and severe asthmatics. Eur. Respir. J., 14, Suppl. 30, 2899.
11. Djukanovic, R., Wilson, J.W., Britten, K.M., Wilson, J.Y., Walls, A.F., Roche, W.R., Howrth, P.H. & Holgate, S.T. (1992) Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis., 145, 669-674.
12. Hood, P.P., Cotter, T.P., Costello, J.F. & Sampson, A.P. (1999) Effect of intravenous corticosteroids on ex vivo leukotriene generation by blood leukocytes of normal and asthmatic patients. Thorax, 54, 1075-1082.
13. Hui, K.P. & Barnes, N.C. (1991) Lung function improvement in asthmatics with cysteinyl-leukotriene receptor antagonist. Lancet, 337, 1062-1063.
14. Juniper, E.F., Kline, P.A., Vanzieleghem, M.A., Ramsfale, E.H., O'Bryne, P.M. & Hargreave, F.E. (1990) Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in non steroid-dependent asthmatics. Am. Rev. Respir. Dis., 142, 832-836.
15. Kemp, J.P., Korenblat, P.E., Scherger, J.E. & Minkwitz, M.C. (1999) Zafirlukast in clinical practice. Results of the accolate clinical experience and pharmacoepidemiology trial (ACCEPT) in patients with asthma. J. Fam. Prac., 48, 425-432.
16. Knorr, B.A., Matz, J. & Bernstein, J.A. (1997) Montelukast (MK-0476) improves asthma over a 2 month treatment period in 6- to 14-years olds. Am. J. Respir. Crit. Care Med., 155, A664.
17. Larsen, J.S. & Susanna, K.J. (1996) Antileukotriene therapy for asthma. Am. J. Health-Syst. Pharm., 53, 2821-2830.
18. Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C. & Peszek, I. (1999) Montelukast added to inhaled beclomethasone Addivity Group. Am. J. Respir. Crit. Care Med., 160, 1862-1868.
19. Liu, M.C., Dube, L.M., Lancester, L. & the Zileuton Study Group (1996) Acute and chronic effects of a lipooxygenase inhibitor in asthma: a 6-month randomized multicentre trial. J. Allergy Clin. Immunol., 98, 859-871.
20. Markopoulou, K.D., Gioulekas, A.S.D., Papakosta, D., Polyzoni, T., Patokas, D., Holevas, M. & Galanis, N. (1999) Serum ECP and conventional tests for asthma monitoring. Eur. Respir. J., 14 Suppl. 30, 2902.
21. National Hearth, Lung and Blood Institute (1997) Guidelines for the Diagnosis and Management of Asthma, 1-50.
22. National Hearth, Lung and Blood Institute (Revised 2002) Guidelines for the Diagnosis and Management of Asthma, NIH Publication No. 02-3658.
23. Pavord, I.D., Ward, R., Woltmann, G., Wardlaw, AJ., Sheller, J.R. & Dworski, R. (1999) Induced sputum eicosanoid concentrations in asthma. Am. J. Respir. Crit. Care Med., 160, 1905-1909.
24. Rahman, I., Morrison, D., Donaldson, K. & Mac Nee, W. (1996) Systemic oxidative stress in asthma, COPD and smokers. Am. J. Respir. Crit. Care Med., 154, 1055-1060.
25. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol., 90 193-201.
26. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. & Edwards, T.B. (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med., 158, 1213-1220.
27. Sedgwick, J.B., Vrtis, R.F., Gourley, M.F. & Busse, W.W. (1988) Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J. Allergy Clin. Immunol. 81, 876-883.
28. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin. Pharmacol. Ther., 54, 430-436.
29. Smith, L.J., Houston, M. & Anderson, J. (1993b) Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. Am. Rev. Respir. Dis., 147, 1461-1464.
30. Smith, L.J., Hanby, M.S., Lavins, B.J. & Simonson, S.G. (1998) A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann. Allergy Asthma Immunol., 81, 43-49.
31. Spector, S.L. (1995) Leukotriene inhibitors and antagonists in asthma. Ann. Allergy Asthma Immunol., 75, 463-473.
32. Suissa, S., Dennis, R., Ernst, P., Sheehy, O. & Wood, D.S. (1997) Effectiveness of the leukotriene receptor antagonist zafirlukast for mild to moderate asthma. Ann. Intern. Med., 126, 177-183.
33. Taylor, I.K., O'Shaughnessy, K.M., Fuller, R.W. & Dollery, C.T. (1991) Effect of cysteinyl leukotriene receptor antagonist ICI-204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet, 337, 690-694.
34. Virchow, J.C., Prasse, A., Naya, I., Summerton, L. & Harris, A. (2000) Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med., 162, 578-585.
35. Wenzel, S.E., Trudeau, J.B., Kaminsky, D.A., Cohn, I., Martin, R.J. & Westcott, J.Y. (1995) Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med., 152, 897-905.
36. Zhang, J., Yu, C., Holgate, S.T. & Reiss, T.F. (1995) Variability and lack of predictive ability of asthma. Am. J. Respir. Crit. Care Med., 152, 45-52.
37. Zoratti, E.M., Sedgwick, J.B., Vrtis, R.F. & Busse, W.W. (1991) The effect of platelet-activated factor on the generation of superoxide anion in human eosinophils and neutrophils. J. Allergy Clin. Immunol., 88, 749-758.